Amgen’s Tavneos faces EU withdrawal after regulators question clinical data integrity, threatening a growth driver and pressuring AMGN shares.
Biotech Kardigan gained nearly 2% in its stock market debut after completing a $400 million initial public offering that priced at the…
Kardigan's upsized $400 million IPO for heart disease therapies highlights growing investor confidence in biotech innovation and sets a favorable precedent for…
Prime Radiant backs Cellares with $50M as the biotech firm gears up for a 2027 IPO, underscoring investor appetite for pre-public opportunities…
Heart health biotech Kardigan files for a $373.3 million U.S. IPO, signaling growing investor interest in cardiovascular therapies and testing the IPO…
Parabilis stock skyrocketed 67% after the drugmaker completed a $745 million IPO and private placement, marking one of the largest biotech IPOs…
Parabilis completes $745 million US IPO, indicating robust biotech investor appetite and potential gains for biotech ETFs.
The Netherlands expands foreign investment screening to AI and biotech, signaling heightened regulatory scrutiny that could derail foreign acquisitions of Dutch tech…
Cancer drugmaker Parabilis aims to raise $475 million in a US IPO, testing biotech investor sentiment as the company progresses its oncology…
Scientists are tracking Ebola survivors in remote mountains to harvest antibodies for a cure, offering new hope against the virus and potential…
Kardigan IPO filing marks a milestone in cardiovascular drug development, highlighting renewed investor interest in biotech innovations beyond oncology.
FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.